Retatrutide (10mg)

Retatrutide is a synthetic peptide that acts as a triple agonist at the GLP-1, GIP, and glucagon receptors simultaneously. This tri-receptor activity profile is what separates it from earlier compounds like semaglutide (GLP-1 only) and tirzepatide (GLP-1/GIP), and is the basis for the significant fat loss results observed in Phase 2 clinical trials.

In the research community, Retatrutide is commonly referred to as Reta peptide or simply Reta. It is also sometimes searched for as Reda peptide or Retatrude — both common misspellings. The shorthand r3ta peptide (using a numeral 3) also appears frequently in online research communities. One particularly common autocorrect error is 'ratatouille peptide' — if that's what brought you here, you're in the right place.

No. Retatrutide is not available as a pre-filled pen, injectable device, or commercial pharmaceutical product in Australia — and is not stocked at retail pharmacies like Chemist Warehouse. It is an investigational research compound that has not been approved for human use by the TGA. Aussie Peptides supplies Retatrutide exclusively as a 10mg lyophilised powder for in-vitro laboratory research purposes. We do not offer 100mg bulk quantities or pen formats — if you have seen these advertised elsewhere, exercise caution regarding the source and purity verification.

Retatrutide is still an investigational compound, not an approved commercial medicine currently available to the public in Australia. Aussie Peptides does not supply Retatrutide as a compounded prescription product or pharmacy medicine — we supply research-grade lyophilised powder for lawful in-vitro laboratory research only. Lilly states that Retatrutide is not yet available for public use, remains in Phase 3 clinical trials, and that public launch depends on the completion of those trials plus regulatory approval, with additional Phase 3 results anticipated in 2026. For researchers searching terms like 'retatrutide compounding pharmacy australia' or 'retatrutide australia release date 2026', the practical distinction is that approved pharmacy release has not happened yet, while research-grade Retatrutide is already available now for legitimate in-vitro research.

Phase 2 clinical trials observed mean body weight reductions of up to 24% over 48 weeks — significantly outperforming semaglutide and tirzepatide in head-to-head comparisons. Subjects also showed dramatic reductions in waist circumference, visceral fat, and improvements across key cardiometabolic markers. The appetite suppression observed was described as profound, with energy intake reductions sustained throughout the trial period.

Retatrutide targets three receptor pathways at once: GLP-1 receptors reduce appetite and slow gastric emptying; GIP receptors enhance insulin sensitivity and may amplify fat loss; and glucagon receptors increase energy expenditure by stimulating the liver to burn more fuel. The combined effect on all three pathways is what produced the 24% mean weight reduction observed in Phase 2 trials.

Retatrutide is supplied as a lyophilized powder and should be reconstituted with bacteriostatic water (BAC water) immediately before use. Inject the BAC water slowly into the vial, directing the stream down the inside wall. Gently swirl to dissolve — do not shake. Once reconstituted, store at 2–8°C and use within 28 days. For a full step-by-step walkthrough, see our complete peptide reconstitution guide.

Store lyophilized Retatrutide vials at -20°C, away from light and moisture. After reconstitution, refrigerate at 2–8°C and use within 28 days. Do not freeze reconstituted solution.

Retatrutide (10mg) is available through Aussie Peptides, with fast domestic shipping to all Australian states and territories. Every vial is dispatched from within Australia — no customs delays, no international freight uncertainty. Each batch undergoes third-party analysis and the Certificate of Analysis is available to view in our CoA library.

Retatrutide (10mg) is priced at $139.99 per vial at Aussie Peptides. All orders ship domestically within Australia, and batch CoAs are available in our CoA library.

Ordering is straightforward — add Retatrutide (10mg) to your cart on the Aussie Peptides website and complete checkout through our secure payment system. All orders are fulfilled domestically and shipped with tracking to any address across Australia. Each batch is third-party tested at ≥99% purity, with the Certificate of Analysis available to view in our CoA library.

Yes — Reta weight loss research is by far the most active area of investigation for this compound. Retatrutide's tri-receptor mechanism (GLP-1, GIP, and glucagon) produces a combined effect on appetite suppression, energy expenditure, and fat oxidation that no single or dual agonist has matched in clinical trials to date. Phase 2 data showing a mean 24% body weight reduction over 48 weeks has made it the benchmark compound for researchers studying next-generation obesity and metabolic disease interventions. Researchers working in this space consistently reach for Retatrutide as the most advanced GLP-1 class compound currently available for study.